Cargando…

Comparison of (68)Ga-DOTA-NaI(3)-Octreotide/tyr(3)-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome

The optimum imaging modality for the screening of multiple endocrine neoplasia type 1 (MEN1)-associated tumors is not well established. Here, we compare the performance of contrast-enhanced CT (CECT) versus (68)Ga DOTA-NOC/TATE PET/CT in MEN1 patients. The retrospective case record study is conducte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patil, Virendra A., Goroshi, Manjunath R., Shah, Hina, Malhotra, Gaurav, Hira, Priya, Sarathi, Vijaya, Lele, Vikram R., Jadhav, Swati, Lila, Anurag, Bandgar, Tushar R., Shah, Nalini S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478292/ https://www.ncbi.nlm.nih.gov/pubmed/32939195 http://dx.doi.org/10.4103/wjnm.WJNM_24_19

Ejemplares similares

Dynamic (68)Ga-DOTA(0)-Tyr(3)-octreotate positron emission tomography-computed tomography for the evaluation of pancreatic neuroendocrine tumors: a pilot study
por: Yin, Hongyan, et al.
Publicado: (2023)

Synchronous carotid body and anterior mediastinal paraganglioma revealed by (18)F-fluorodeoxyglucose and (68)Ga-DOTA(0)-Tyr(3)-octreotate positron emission tomography-computed tomography
por: Xie, Hangyu, et al.
Publicado: (2023)

Neuroendocrine prostate cancer or prostatitis? An unusual false positive on gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography in a patient with known metastatic neuroendocrine tumor
por: Schmidt, Matthew Q, et al.
Publicado: (2019)

Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate
por: Ma, Michelle T., et al.
Publicado: (2015)

Effects of therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate on endocrine function
por: Teunissen, Jaap J. M., et al.
Publicado: (2009)

Bone metastasis from a neuroendocrine tumor detected by 99m-technetium-hydrazinonicotinyl-Tyr3-octreotide single-photon emission computed tomography/computed tomography
por: Kamaleshwaran, Koramadai Karuppusamy, et al.
Publicado: (2013)

Validation of Quality Control Parameters of Cassette-Based Gallium-68-DOTA-Tyr3-Octreotate Synthesis
por: Sammartano, Antonino, et al.
Publicado: (2020)

Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Forrer, Flavio, et al.
Publicado: (2009)

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate
por: Chan, Ho Sze, et al.
Publicado: (2016)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Alveolar Soft Part Sarcoma Presenting as Hypervascular Adrenal Metastasis
por: Goroshi, Manjunath, et al.
Publicado: (2018)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Radiological differentiation of phaeochromocytoma from other malignant adrenal masses: importance of wash-in characteristics on multiphase CECT
por: Goroshi, Manjunath, et al.
Publicado: (2019)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [(177)Lu-[DOTA0, Tyr3]-octreotate
por: Santoro, Lore, et al.
Publicado: (2018)

177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT
por: Mazzara, Christophe, et al.
Publicado: (2022)

Fluorodeoxyglucose positron emission tomography-computed tomography findings in a case of xanthogranulomatous pyelonephritis
por: Joshi, Prathamesh, et al.
Publicado: (2013)

Inflammatory Myofibroblastic Tumor: Findings on (68)Ga-DOTA-NOC Positron-emission Tomography-Computed Tomography
por: Tripathy, Sarthak, et al.
Publicado: (2020)

Hypoglycemia-Triggered Motion Artifact on (68)Ga-DOTA-TOC Positron Emission Tomography/Computed Tomography
por: Chandra, Piyush, et al.
Publicado: (2021)

Comparison of (68)Ga-DOTANOC PET/CT and contrast-enhanced CT in localisation of tumours in ectopic ACTH syndrome
por: Goroshi, Majunath R, et al.
Publicado: (2016)

Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
por: Kim, Chul, et al.
Publicado: (2020)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Failure of functional imaging with gallium-68-DOTA-D-Phe1-Tyr3-octreotide positron emission tomography to localize the site of ectopic adrenocorticotropic hormone secretion: a case report
por: Gani, Linsey U, et al.
Publicado: (2011)

(68)Ga-Tetraazacyclododecane Tetraacetic Acid-DPhe1-Tyr3-Octreotate Positron Emission Tomography/Computed Tomographic Findings of Large-Cell Neuroendocrine Carcinoma of the Lung in a Child
por: Filizoglu, Nuh, et al.
Publicado: (2022)

Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report
por: Sampaio Vieira, Tiago, et al.
Publicado: (2018)

Fludeoxyglucose positron emission tomography-computed tomography in limbic encephalitis
por: Patil, Sushanti, et al.
Publicado: (2014)

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model
por: Ullrich, Martin, et al.
Publicado: (2016)

Aortoarteritis: Could it be a form of catecholamine-induced vasculitis?
por: Sarathi, Vijaya, et al.
Publicado: (2013)

(68)Ga-DOTA-E-[c(RGDfK)]2 positron emission tomography–computed tomography in the evaluation of hepatic hemangioendothelioma epithelioid
por: Soldevilla-Gallardo, Irma, et al.
Publicado: (2019)

Gender differences in macroprolactinomas: a single centre experience
por: Khare, Shruti, et al.
Publicado: (2015)

Carcinoma of unknown primary of neuroendocrine origin: Accurate detection of primary with (68)Ga-labelled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI3-Octreotide positron emission tomography/computed tomography enterography
por: Jain, Tarun Kumar, et al.
Publicado: (2014)

Correlation between Standardized Uptake Value of (68)Ga-DOTA-NOC Positron Emission Tomography/Computed Tomography and Pathological Classification of Neuroendocrine Tumors
por: Kaewput, Chalermrat, et al.
Publicado: (2018)

Molecular Imaging to the Surgeons Rescue: Gallium-68 DOTA-Exendin-4 Positron Emission Tomography-Computed Tomography in Pre-operative Localization of Insulinomas
por: Pallavi, UN, et al.
Publicado: (2019)

In Vivo Measurement and Characterization of a Novel Formulation of [(177)Lu]-DOTA-Octreotate
por: Bailey, Dale L, et al.
Publicado: (2016)

68Ga-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC)-PET/CT in a Suspected Case of Recurrent Meningioma
por: Jain, Sachin, et al.
Publicado: (2017)

A Case Series of Neurolymphomatosis: Role of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Scan Reiterated
por: Gupta, Manoj, et al.
Publicado: (2023)

A rare cause of tube arcing artifact seen in computed tomography image of a positron emission tomography/computed tomography scanner
por: Mithun, Sneha, et al.
Publicado: (2016)

Primary Pleuropulmonary Synovial Sarcoma on Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Scan
por: Shah, Digish, et al.
Publicado: (2017)

Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of (177)Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
por: Shah, Rashmi G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vod9mvh5httnen73ide1mkq3ka